Are Incentives Out Of Balance With Patient Need?
Incentives matter; they motivate us to do things. There is renewed interest in just what motivates the life sciences industry to make the choices it does when determining the diseases it will focus on, and how much effort it puts in. This stems from concern about too much effort going into some areas, and too little in others.
You may also be interested in...
The COVID-19 pandemic will have a lasting impact on the world, including on Health Technology Assessment (HTA). The debate on how HTA should change as a result of COVID-19 is gaining momentum, but could a wider approach to value and a higher threshold be a false dawn?
The signs suggest that Nicola Magrini, the new director general of the Italian medicines regulator, AIFA, will follow in the footsteps of his predecessor in fighting for transparency in drug pricing.
In Belgium, there are increasing tensions between drug price transparency and getting the best deal for the Belgian government.